Conduit Pharmaceuticals (NASDAQ:CDT) Issues Quarterly Earnings Results

Conduit Pharmaceuticals (NASDAQ:CDT) released its quarterly earnings data on Friday. The company reported ($20.33) EPS for the quarter, Zacks reports.

Conduit Pharmaceuticals Price Performance

Shares of Conduit Pharmaceuticals stock traded up $0.12 during trading on Friday, hitting $0.89. The stock had a trading volume of 4,959,941 shares, compared to its average volume of 1,016,669. Conduit Pharmaceuticals has a 12 month low of $0.73 and a 12 month high of $392.00. The firm’s fifty day simple moving average is $2.03 and its 200-day simple moving average is $7.20.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.